Bladder Cancer Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working

Urine is stored in the bladder, which is a hollow organ in the lower abdomen. Bladder cancer develops in the bladder's lining. Transitional cell carcinoma, commonly known as urothelial carcinoma, is the most frequent type of bladder cancer. Smoking is one of the leading causes of bladder cancer. Bladder cancer is frequently detected in its early stages.

Bladder cancer was rated 10th among all cancers in the globe, with 549,000 new cases and 200,000 deaths each year; it contributed 3.4 percent to the overall cancer burden worldwide. There were 18,921 new cases and 10,231 deaths in India.

DelveInsight’s “Bladder Cancer – Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Bladder Cancer, historical and forecasted epidemiology as well as the Bladder Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

Some of the key facts of the Bladder Cancer Market Report:

  •  An Estimated 573,278 people were diagnosed with Bladder Cancer WorldWide in 2020

  •  Bladder Cancer is the fourth most common cancer among the men

  • There has been a decline of 1%/year in the number of cases of Bladder Cancer in the US from 2009-to 2018 

  • Bladder cancer was rated 10th among all cancers in the globe, with 549,000 new cases and 200,000 deaths each year 

  • While the specific aetiology of bladder cancer is unknown, it has been related to a number of risk factors, including tobacco use and exposure to certain chemicals and gases. In addition, persons who have a family history of bladder cancer are more likely to get the disease

Key benefits of the report: Request a sample- https://www.delveinsight.com/sample-request/bladder-cancer-market

 

  1. The Bladder Cancer market report covers a descriptive overview and comprehensive insight of the Bladder Cancer Epidemiology and Bladder Cancer  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

  2. The Bladder Cancer market report provides insights on the current and emerging therapies.

  3. Bladder Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.

  4. The Bladder Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Bladder Cancer market. 

Got queries? Click here to know more about the Bladder Cancer Market Landscape

Bladder Cancer Symptoms: 

  • Blood in the Urine can be seen

  • Pain is felt while urinating

  • Back Pain

  • Pain in The Pelvic area

Bladder Cancer Market: 

The dynamics of the Bladder Cancer market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as and others during the forecasted period 2018-2030. 

The key players working in the field of Bladder Cancer are the - Swiss Group for Clinical Cancer Research, University of Kansas Medical Center, University of Oklahoma, Radiation Therapy Oncology Group, National Cancer Institute (NCI), and ImmunityBio, Inc. 

Learn more by requesting for sample @ Bladder Cancer Market Landscape 

Bladder Cancer Pipeline Therapies:

  •  VPM1002BC

  • Ascorbic Acid

  • Avelumab

  • Cisplatin

  •  Paclitaxel

  • Mitomycin C

  • N-803 and BCG 

Bladder Cancer and Key Companies: 

  • Swiss Group for Clinical Cancer Research

  • University of Kansas Medical Center

  • University of Oklahoma

  • Radiation Therapy Oncology Group

  • National Cancer Institute (NCI)

  • ImmunityBio, Inc. 

Click here to read more about Bladder Cancer Market Outlook 2032

Comments

Post a Comment

Popular posts from this blog

The Fight for Market Supremacy: OPDIVO vs. KEYTRUDA in Japan’s Cancer Treatment

Image
  Analyzing OPDIVO’s Pre-2022 Sales Decline and KEYTRUDA’s Market Ascendancy Before 2022, OPDIVO, developed by Bristol-Myers Squibb (BMS), faced a significant sales decline in Japan’s PD-1 inhibitor market. Despite its initial success, the PD-1 and PD-L1 inhibitors faced challenges from new competitors and evolving market dynamics. One key competitor was Merck's KEYTRUDA, which steadily gained market share due to its broader range of approved indications and successful clinical trial outcomes. KEYTRUDA’s market ascendancy was marked by its approval for various cancers, including melanoma, non-small cell lung cancer, and urothelial carcinoma, among others, making it a versatile choice for oncologists. How OPDIVO Outpaced KEYTRUDA in Japan’s Pharmaceutical Market In 2022, OPDIVO made a remarkable comeback, outpacing KEYTRUDA in Japan’s pharmaceutical market. This resurgence was driven by several strategic moves by BMS. The company expanded OPDIVO’s indications, securing approvals fo...
Read more

Next-generation Nephrotic Syndrome Treatments: A Glimpse into the Future

Image
Nephrotic syndrome , a condition characterized by the presence of protein in the urine, swelling, low protein levels in the blood, and high cholesterol levels, poses significant challenges for patients and healthcare providers alike. While traditional approaches such as steroids and immunosuppressants have been the mainstay of treatment, emerging therapies offer new hope for individuals battling this debilitating condition. Let's delve into the landscape of nephrotic syndrome treatment, exploring both the current approaches and the promising pipeline therapies on the horizon. Traditional Approaches for Nephrotic Syndrome Treatment: Steroids and Immunosuppressants Historically, steroids and immunosuppressants have been the cornerstone of nephrotic syndrome treatment . These medications help reduce inflammation and suppress the immune system's abnormal response, thereby alleviating symptoms and slowing disease progression. However, their efficacy can vary, and long-term use may b...
Read more

FDA Approval Marks New Hope: Eli Lilly’s Donanemab for Alzheimer’s Disease

Image
  The Birth of a Breakthrough Eli Lilly’s groundbreaking drug, Donanemab, has recently received FDA approval, marking a significant milestone in Alzheimer’s disease treatment . This innovative therapy, designed to target and reduce amyloid plaques in the brain, offers new hope for patients battling this debilitating condition. Donanemab’s approval comes at a pivotal moment, as it represents a major advancement in the Alzheimer’s disease pipeline, promising improved outcomes for those affected. Navigating Regulatory Waters The journey of Donanemab through the regulatory landscape was complex, characterized by rigorous scrutiny and extensive clinical trials. Eli Lilly’s success in obtaining FDA approval highlights the drug’s potential to revolutionize Alzheimer’s disease therapies . This regulatory endorsement not only underscores the efficacy and safety of Donanemab but also sets a new standard for the evaluation of future treatments. Donanemab: Cost and Coverage As with many groun...
Read more